片仔癀(600436.SH)：PZH2108片Ⅱa期临床试验完成首例受试者入组

Core Viewpoint - The company Pianzaihuang (600436.SH) has announced the initiation of a Phase IIa clinical trial for its innovative chemical drug PZH2108, aimed at evaluating its safety, tolerability, preliminary clinical efficacy, pharmacokinetics, and pharmacodynamics in cancer patients [1] Group 1: Clinical Trial Details - The Phase IIa clinical trial for PZH2108 is designed as a multicenter, randomized, double-blind, placebo-controlled study [1] - The primary endpoints of the trial include the occurrence of adverse events during the treatment period (including serious adverse events) and abnormal safety assessments (including vital signs, physical examinations, laboratory tests, and 12-lead electrocardiograms) [1]